Cantor Fitzgerald reiterates Neutral rating on Merck stock at $120
Cantor Fitzgerald has maintained its Neutral rating on Merck & Co. stock (MRK) at $120.00, citing the early stoppage of an adjuvant melanoma study due to overwhelming efficacy. The firm highlighted that Merck shares contributed over $40 billion to the drug's market capitalization during the first half, attributing significant credit to the company's efforts beyond melanoma.
Currently trading at $149.50, near its 52-week high of $156.92, the stock has delivered a remarkable 91% return over the past year. However, InvestingPro analysis suggests the stock may be slightly overvalued relative to its Fair Value. The RFS hazard ratio, anticipated to fall between 0.6 and 0.65, will be a key focus for investors.
Analysts have shown varied opinions on Merck's prospects, with Guggenheim raising its target to $170 and Berenberg to $137, while UBS downgraded the stock to Neutral. Despite the mixed perspectives, Merck's earnings are projected to remain stable through 2029 before potential growth.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
